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Background: Mice with the cystic fibrosis transmembrane conductance regulator (Cftr) gene knocked out develop osteopenia. To determine
whether this phenotype is present in cystic fibrosis mouse models with the ΔF508 Cftr mutation we assessed the femora of adult FVB/N Cftrtm1Eur
and C57BL/6 Cftrtm1Kth mice.
Methods: Bone disease, relative to littermate controls, was measured using histology, densitometry and quantitative imaging.
Results: C57BL/6 Cftrtm1Kth mice had shorter femurs and bones of lower volume due to thinner trabeculae, compared to wild type littermates.
FVB/N Cftrtm1Eur mice also presented a lower bone volume which was due to significantly fewer trabeculae in this strain. Osteoblast and
osteoclast numbers did not differ between CF and controls, for either of FVB/N Cftrtm1Eur or C57BL/6 Cftrtm1Kth mice. The bone architecture of
FVB/N Cftrtm1Eur mice did not significantly differ from that of C57BL/6 Cftrtm1Kth mice.
Conclusions: An osteopenic bone disease is evident in adult ΔF508-Cftr cystic fibrosis mouse models.
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Cystic fibrosis (CF) is caused by defects in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene and these
lead to well described pathologies affecting the lung, intestine,
and pancreas [1]. An additional phenotype developing in CF
patients is bone disease, which is manifest by low bone mineral
density (BMD) and increased fracture rates [2,3] in this
population. Although factors such asmalnutrition, steroid therapy
and lung disease likely contribute to the bone complications in CF
patients [2,4], King et al. [5] have shown that the commonΔF508
mutation in the chloride-ion channel encoded by CFTR is an
independent risk factor for bone disease in CF.
Mouse models with specific alterations in Cftr have been
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doi:10.1016/j.jcf.2010.05.001these include mice which produce no Cftr protein, such as the
Cftrtm1Unc line developed by Snouwaert et al. [7], or mice
producing the Cftr protein with theΔF508 mutation. Mice of the
latter type include the Cftrtm1Eur line which was created with a hit
and run technique [8] and these mice express the mutant allele at
the same level at whichwild typemice express the wild type allele
in assayed tissues including the intestine [9]. A second line,
Cftrtm1Kth mice [10], express the mutated allele at a level of 25%
relative to that of wild type mice expressing the wild type allele
and this low level of expression in the intestine [10], but not other
tissues including the lung, likely contributes to the lethal intestinal
phenotype mice of this strain can develop. Although known to be
expressed in bone [11,12] and in chondrocytes [13], the level of
expression ofCftr in the bones of theseΔF508Cftrmousemodels
has not been reported.
Previous studies have shown that Cftrtm1Unc mice on both a
genetically mixed [14] and inbred strain, BALBc/J [15],
background present a bone disease characterised by reduced bone
volume of the femoral tissue which featured fewer thinner
trabeculae. Whether FVB/N Cftrtm1Eur or C57BL/6 Cftrtm1Kthd by Elsevier B.V. All rights reserved.
Fig. 1. Femur length and bone mineral density inΔF508 Cftrmouse models. CF
and control (Cftr +/+) mice were maintained on PEGLYTE® treated drinking
water until euthanasia at 11–15 weeks of age. Bone lengths (A) were measured
on high resolution Faxitron X-rays and bone mineral density (B) on a PixiMus
densitometer. Values represent the mean±SD of n=4–7 mice per group.
*Significant difference between groups, pb0.05.
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mice to be used as a model of this pathology of cystic fibrosis, is
unknown. The current study was undertaken to determine whether
the ΔF508 Cftr mutation leads to a bone phenotype in mice.
2. Materials and methods
2.1. Mice
Cftrtm1Eur heterozygous mice [8], which had been backcrossed
for 13 generations to the FVB/N strain, were obtained from Dr. B.
Scholte of the University Medical Centre Rotterdam, and the
C57BL/6 (B6) Cftrtm1Kth strain [10] from Dr. C. Bear of the
Hospital for Sick Children (Toronto, Canada). Cystic fibrosis mice
of each strain and Cftr +/+ littermate controls were derived from
heterozygous breeding pairs, genotyped as in [16, www.jax.org]
and maintained at the Meakins-Christie Laboratories of McGill
University. To circumvent the premature death due to intestinal
disease, all micewere fed standard chow and received PEGLYTE®
(17.8 mmol/L polyethylene glycol, Pharma Science, Montreal,
Canada) in their drinkingwater as described previously [15,17,18].
At 11–15 weeks of age the mice were weighed, euthanised with a
lethal dose of anaesthetic and one femur was removed. Relative to
sexualmaturity at 6–8 weeks of age, the bone disease assessment is
of young adult mice. All animal procedures were performed in
accordance with the McGill University guidelines set by the
Canadian Council on Animal Care.
2.2. Radiological imaging
Phenotyping procedures were performed as described previ-
ously [15]. High resolution X-rays of the femora were obtained
with a Faxitron MX20/DC2 (Faxitron X-ray Corporation,
Wheeling IL, USA), equipped with an FPX-2 Imaging system
(Dalsa Medoptics, Waterloo, Ontario, Canada), and used to
measure femur length. A Lunar PixiMUS 1.46 instrument (GE-
Lunar, Madison, WI, USA) was then used to measure bone
mineral density on bones dissected free of soft tissue. Bones were
fixed overnight in 4% paraformaldehyde, rinsed three times with
PBS and scanned on a Skyscan 1072 micro CT instrument
(Skyscan, Antwerp, Belgium) to assess bone morphometry.
Image acquisition was performed at 45 kV, 222 µA for a 2.24
second exposure at 50× with a 0.9° rotation between frames.
These two-dimensional images were used to reconstruct three-
dimensional images for quantitative analysis using 3D Creator
software supplied with the instrument. The area of interest
selected for quantification of trabecular bone was located
immediately distal to the growth plate and extended for
2.25 mm towards the metaphysis of the femur.
2.3. Histochemistry
The bone tissue was embedded in polymethylmethacrylate at
low temperature and 4 µmsectionswere cut and stained for alkaline
phosphatase (ALP) activity in osteoblasts or tartrate resistant acid
phosphatase (TRAP) in osteoclasts as described previously [15].
Cell numbers were scored by an investigator, blinded to mousestrain andCftr genotype, using a single section from 4 to 7mice per
group. Osteoclast percentage was determined by measuring the
area of TRAP positive cells present per unit area of the metaphysis.
Osteoblast cell numbers were counted and normalised to the length
of the growth plate in each section.
2.4. Statistical analysis
Results are expressed as the mean±SD and differences
between groups of mice were determined using Student's t test.
3. Results
3.1. Femur length and bone mineral density in CF mice
To determine whether the bone disease inCftr knockout mice is
evident in those with the ΔF508 mutation in Cftr length and
mineral densitymeasuresweremade in femora extracted frommice
of two strains and from age, sex and strain matched Cftr +/+
(control) mice. As shown in Fig. 1 the bones of the B6 Cftrtm1Kth
mice were shorter than those of control mice but this difference was
not evident in the mice of the FVB/N Cftrtm1Eur strain. In addition,
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control mice (20.7±1.6 (std. dev. vs. 26.9±3.0 g, p=0.03) while,
again, this difference was not evident in the mice of the FVB/N
Cftrtm1Eur strain (26.1±3.8 vs. 29.8±2.5 g, p=0.08). Femoral bone
mineral density was not significantly different between CF and
control mice of either strain (Fig. 1B), but the density of the FVB/N
Cftrtm1Eur bones exceeded that of B6 Cftrtm1Kth mice ( p=0.027).
Finally, inCftr +/+ control mice, no significant differences between
strainswere evident in either bonemineral density or in length (each
pN0.19).
3.2. Bone architecture of CF mice
To investigate whether the osteopenia of BALB Cftrtm1Unc CF
mice is evident in theΔF508CftrmousemodelsmicroCT imagingFig. 2. Architecture of the distal femur of C57BL/6Cftrtm1Kth CF and control mice. Bo
tissue, fixed and scanned on a Skyscan 1072 micro CT equipped with 3D Creator a
sectional scans (b–d) demonstrated thinner trabeculae and cortical thinning of CF bof the femoral tissuewas completed. As shown in Figs. 2 and 3 and
quantified in Table 1, the bones from the FVB/N Cftrtm1Eur mice
and of B6Cftrtm1Kth micewere thinner and had fewer, or narrower,
trabeculae compared to controls. Among the CFmousemodels, no
strain dependence in bone architecture was detected ( pN0.11),
while in the Cftr +/+ (control) mice, trabecular thickness was
dependent on strain ( p=0.029), and was lower for the FVB/N
mice. The other parameters did not significantly differ by strain
among the control mice (all pN0.10), as shown in Table 1.
3.3. Osteoblast and osteoclast quantification
To determine whether the lower bone volume of B6Cftrtm1Kth
and FVB/N Cftrtm1Eur mice coincided with reduced levels of
osteoblasts, or increased numbers of osteoclasts in the tissue, bonenes from CF (upper) andCftr +/+ control (lower) mice were dissected free of soft
nalytical software. Three-dimensional re-construction (a) and two-dimensional
ones.
Fig. 3. Architecture of the distal femur of FVB/N Cftrtm1Eur and control mice. Bones from CF (upper) and Cftr +/+ control (lower) mice were dissected free of soft
tissue, fixed and scanned on a Skyscan 1072 micro CT equipped with 3D Creator analytical software. Three-dimensional re-construction (a) and two-dimensional
sectional scans (b–d) demonstrated fewer trabeculae and cortical thinning of FVB/N Cftrtm1Eur bones.
Table 1










BV/TV (%) 6.57*±1.05 7.86±1.13 6.81*±1.93 11.22±4.14
SMI 2.15*±0.08 2.06±0.04 2.27±0.17 2.02±0.35
TrTh (μm) 50.6±3.1 50.5±5.0 51.8*±2.8 56.7**±3.9
Tr Sp (μm) 291±11 254±44 251±36 216±44
TrNo 1.29*±0.16 1.56±0.22 1.32±0.40 1.95±0.68
CF and control (Cftr +/+) mice were maintained on PEGLYTE® treated
drinking water and euthanised at 11–15 weeks of age. Bone volume (BV/TV),
the ratio of plate/rod-like structures (SMI), and trabecular thickness (TrTh)
separation (TrSp) and number (TrNo) were quantified using micro computed
tomography. Values represent the mean±SD. * Significant difference between
CF and control mice; pb0.05. ** Significant difference between strains; pb0.05.
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types and positive cells enumerated. As shown in Fig. 4A tissue
from CF and control mice, for both the B6 Cftrtm1Kth and FVB/N
Cftrtm1Eur mice contained numerous ALP positive (osteoblast)
cells adjacent to the growth plate. The numbers of osteoblasts per
unit length of growth plate did not differ between CF and control
mice in either strain. Similarly, TRAP positive cells (osteoclasts)
were evident in the region of the growth plate and the distal
metaphysis in both CF and control mice and as shown in Fig. 4C
the percentage of bone tissue with TRAP positive cells did not
differ between CF and controls, in either of FVB/N or B6 mice.
4. Discussion
This study was undertaken to determine whether the bone
phenotype evident in cystic fibrosis mouse models created with
Fig. 4. Osteoblast and osteoclast numbers inΔF508Cftrmousemodels. A. Osteoblasts were counted on representative alkaline phosphatase stained sections (red cells) and
B.Osteoclasts were counted on representative tartrate resistant acid phosphatase stained sections (brownish red cells) of plastic embedded femoral bone from 4 to 7mice per
group. Representative images from C57BL/6 Cftrtm1Kth (upper left); C57BL/6 Cftr +/+ control (upper right); FVB/N Cftrtm1Eur (lower left); and FVB/N Cftr +/+ control
(lower right); magnification=100×. C. Positive cells (osteoblasts) per mm of growth plate (left) and % osteoclast staining in tissue. Values are expressed as mean±SD.
Significantly different from control, *pb0.05.
243J. Paradis et al. / Journal of Cystic Fibrosis 9 (2010) 239–245the UNC, or knockout, mutation in Cftr [14,15,19] is present in
CF mouse models carrying a ΔF508 mutation in Cftr. We have
shown that in adult B6Cftrtm1Kth mice the femora are significantlyshorter and of compromised trabecular architecture compared
with wild type control mice. Secondly, FVB/N Cftrtm1Eur mice
had similar bone mineral density as their littermates but still
Fig. 4 (continued).
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BALB [15] Cftrtm1Unc mice, an osteopenic phenotype has now
been documented in four adult cystic fibrosis mouse models,
including FVB/N Cftrtm1Eur mice which express the clinically
common ΔF508 mutation in Cftr at wild type levels.
The bone phenotype presented for B6 Cftrtm1Kth mice, on
PEGLYTE® treatment to reduce the incidence of lethal intestinal
obstructions, agrees well with that reported by Pashuck et al. [19]
for gut-corrected B6 Cftrtm1Unc mice in that both investigations
describe the adult CFmice to have reductions in femur length and
thinner trabeculae, compared to littermates. As gut-corrected CF
mice do not suffer the lethal intestinal complications which
necessitated dietary intervention to overcome limited survival in
our study, this finding indicates that the bone phenotype presented
is not that of a selected population.
Also in agreement with previously reported data [10] the B6
Cftrtm1Kth mice studied here were significantly smaller than the
wild type littermates of the same age, and the reported bone
phenotype in part reflects this size difference. Indeed, in a prior
study [15] we showed control mice to have increased weight
and bone mineral density at 12 weeks of age compared to at
8 weeks, while in BALB Cftrtm1Unc CF mice these changes
were evident at a later age, in 28 week old mice compared to
those at 12 weeks. The CF bone disease features of low bone
volume due to fewer, thinner, trabeculae, however, were still
evident in the 28 week old mice. The growth delay, therefore,
appears to affect the density of bones in mice, more than the
architecture. This conclusion is reflected in the phenotype of the
FVB/N Cftrtm1Eur mice which displayed significantly reduced
bone volume while weight, length and mineral density measures
were similar to those of wild type mice.The mouse strains evaluated here have not been reported to
develop overt lung disease [8,10], but studies of the bronchoal-
veolar lavage ofCftrtm1Eur mice have revealed it to differ from that
of wild type mice. In detail, increased numbers of lavage
neutrophils and macrophages have been reported [16,20,21] for
Cftrtm1Eur mice of a mixed 129/FVB genetic background while
Meyer et al. [21] also demonstrated the peritoneal lavage of these
animals to have greater inflammatory cell counts. Finally, in their
work the lavage was shown to have an increased amount of
chemokine C–C motif ligand-2 (CCL2) relative to that in control
littermates. As altered levels of cytokines and chemokines,
including CCL2 [22], can influence osteoclastogenesis, the
reduced bone volume in these mice may be related to an inherent
inflammatory state in CF mice. Supporting this conjecture is the
work of Haworth et al. [23], who showed bone mineral content
measures to be negatively correlatedwith serum interleukin-6 and
C reactive protein levels in CF patients. Whether the FVB Cftr-
tm1Eur evaluated here present the same inflammation as that of
mixed background Cftrtm1Eur mice is not known.
Cell-type specific staining was used to show the CF and
control mice of the strains evaluated here to not differ in numbers
of osteoblasts or osteoclasts, in agreement with the work of
Pashuck et al. [19]. Given the lower bone volume in the FVB/N
Cftrtm1Eur and B6 Cftrtm1Kth CF mouse models and previous
reports of altered bone formation rates in CF mice [14,19] this
finding may indicate that a deficiency in Cftr does not influence
bone cell numbers but may alter the cell function. More study is
needed to elucidate how a deficiency in Cftr could influence cell
function but a recent report [24] showed inhibition of CFTR in
primary human osteoblast cultures to significantly decrease
osteoprotegerin secretion, a condition which, as this protein
negatively regulates osteoclast recruitment and activation [25], if
presented by CF patients or mice, would be expected to result in
increased bone resorption. Secondly, as Cftr functions in both
chloride and bicarbonate transport [26] defects in the latter
function could contribute to bone disease, given that bicarbonate
levels influence osteoclast function [27].
In summary, through microCT imaging we have shown that
cystic fibrosis mice created with reduced expression levels of
ΔF508-Cftr, or wildtype expression levels ofΔF508-Cftr to present
an osteopenic bone disease which supports the conclusion that a
primary defect in Cftr contributes to the bone disease evident in
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